Oculis Holding AG (OCS) Net Cash Flow (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Net Cash Flow of $10.6 million in Q1 2026, down 87.5% quarter-over-quarter from $84.5 million in Q4 2025, and down 88.82% on a YoY basis from $94.4 million in Q1 2025.
Oculis Holding AG (OCS) Net Cash Flow (2022 - 2026) Analysis & Trends
Oculis Holding AG's Net Cash Flow history runs 5 years deep, the most recent figure standing at $10.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 88.82% year-over-year to $10.6 million; the TTM figure through Mar 2026 stood at $56.0 million (down 40.7% YoY), while the FY2025 annual figure was $74.7 million, up 693.26% from the prior year.
- Net Cash Flow was $10.6 million for Q1 2026 at Oculis Holding AG, down from $84.5 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $94.4 million in Q1 2025 to a low of -$20.1 million in Q2 2025.
- Historically, Net Cash Flow has averaged $14.7 million across 5 years, with a median of -$5.7 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow plunged 205.76% in 2023, then surged 1030.89% in 2025.
- A 5-year view of Net Cash Flow shows it stood at -$8.6 million in 2022, then soared by 219.38% to $10.3 million in 2023, then slumped by 187.95% to -$9.1 million in 2024, then jumped by 1030.89% to $84.5 million in 2025, then tumbled by 87.5% to $10.6 million in 2026.
- The last three Net Cash Flow figures came in at $10.6 million (Q1 2026), $84.5 million (Q4 2025), and -$18.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 664,983.53 |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 10.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.56 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 84.47 Mn |
| Dec 31, 2025 | 84.47 Mn |
| Sep 30, 2025 | -18.91 Mn |
| Sep 30, 2025 | -18.91 Mn |
| Jun 30, 2025 | -20.10 Mn |
| Jun 30, 2025 | -20.10 Mn |
| Mar 31, 2025 | 94.39 Mn |
| Mar 31, 2025 | 94.39 Mn |
| Dec 31, 2024 | -9.07 Mn |
| Dec 31, 2024 | -9.07 Mn |
| Sep 30, 2024 | -13.33 Mn |
| Sep 30, 2024 | -13.33 Mn |
| Jun 30, 2024 | 22.47 Mn |
| Jun 30, 2024 | 22.47 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Dec 31, 2023 | 10.32 Mn |
| Dec 31, 2023 | 10.32 Mn |